Several cellular and molecular therapies such as stem cell therapy, cell replacement therapy, gene modification therapy and tolerance induction therapy have been researched to procure a permanent cure for Type 1 Diabetes.However, due to the induction of undesirable side effects, their clinical utility is questionable. These anti-diabetic therapies can be modified with nanotechnological tools for reducing adverse effects by selectively targeting genes and/or receptors involved directly or indirectly in the diabetes pathogenesis such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, human leukocyte antigen [HLA] gene, miRNA gene and hepatocyte growth factor [HGF] gene. This paper will review the utilities of nanotechnology in stem cell therapy, cell replacement therapy, beta-cell proliferation strategies, immune tolerance induction strategies and gene therapy for type 1 diabetes management.